Company-wide revenue
Reported revenue in 2021 ¥162.6B Reported revenue in 2025 ¥241.24B
- growth amount
- +¥78.63B
- growth annualized
- +10.4%
- growth total
- +48.4%
Japanese company profile · 2590
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: ダイドーグループホールディングス株式会社
Name follows the English name recorded in EDINET filer data. English company name source
FY2025 · fiscal year ended January 2026Latest filing date: 2026-04-14What does this company do?
In its FY2025 public filing, DyDo GROUP HOLDINGS,INC. reports Domestic Beverages Business, Overseas Beverages Business, Pharmaceuticals-related Business, Food Products, and 1 other reported businesses. The page shows business-level revenue and profit where the source disclosures support comparison.
DyDo GROUP HOLDINGS,INC.'s largest reported business by revenue in FY2025 was Domestic Beverages Business.
The business with the highest reported segment profit in FY2025 was Overseas Beverages Business.
FY2025 · fiscal year ended January 2026 · View original filing ↗ The source document may be in Japanese.
JGAAP · Consolidated company-wide
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
RevenueDomestic Beverages Business
ProfitOverseas Beverages Business
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Domestic Beverages Business | ¥142.65B ↗ | 59.1% | −¥2.28B ↗ | -1.6% |
| Overseas Beverages Business | ¥65.34B ↗ | 27.1% | ¥7.55B ↗ | 11.6% |
| Food Products | ¥19.57B ↗ | 8.1% | ¥487M ↗ | 2.5% |
| Pharmaceuticals-related Business | ¥13.44B ↗ | 5.5% | ¥829M ↗ | 6.2% |
| Orphan Drugs Business | ¥606M ↗ | 0.3% | −¥321M ↗ | -53.0% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended January 2026. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Domestic Beverages Business | ¥118.08B | ¥109.77B | ¥153.62B | ¥147.52B | ¥142.65B |
| Overseas Beverages Business | ¥12.78B | ¥18.91B | ¥26.44B | ¥56.26B | ¥65.34B |
| Pharmaceuticals-related Business | ¥11.13B | ¥12.52B | ¥12.96B | ¥13.12B | ¥13.44B |
| Food Products | ¥21.16B | ¥19.57B | ¥20.7B | ¥20.65B | ¥19.57B |
| Orphan Drugs Business | — | — | — | ¥8M | ¥606M |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
Reported revenue in 2021 ¥162.6B Reported revenue in 2025 ¥241.24B
This describes a reported period; it is not a forecast.
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
Source
FY2025 · fiscal year ended January 2026
The source document may be in Japanese.
Filing ID: S100XYDT
View original filing ↗